Here's Why You Should Hold on to Abbott (ABT) Stock for Now

Zacks05-21

Abbott Laboratories (ABT) is well-poised to grow in the coming quarters, backed by its Nutrition business, which continues to recover shares and grow its Adult business. Within Diabetes care, Libre’s ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2437426174?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","is_english":true,"pubTime":"2024-05-21 21:29","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2437426174","market":"us","top_or_hot":-1,"title":"Here's Why You Should Hold on to Abbott (ABT) Stock for Now","media":"Zacks","content":"<div>\n<p>Abbott Laboratories (ABT) is well-poised to grow in the coming quarters, backed by its Nutrition business, which continues to recover shares and grow its Adult business. Within Diabetes care, Libre’s ...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-why-hold-abbott-abt-132900987.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why You Should Hold on to Abbott (ABT) Stock for Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why You Should Hold on to Abbott (ABT) Stock for Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-21 21:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/heres-why-hold-abbott-abt-132900987.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Abbott Laboratories (ABT) is well-poised to grow in the coming quarters, backed by its Nutrition business, which continues to recover shares and grow its Adult business. Within Diabetes care, Libre’s ...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-why-hold-abbott-abt-132900987.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1989763427.SGD","symbol_name":"CPR Invest - Food For Generations A2 Acc SGD-H","start_time":0,"source_url":"https://finance.yahoo.com/news/heres-why-hold-abbott-abt-132900987.html","article_id":"2437426174","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2437426174","pubTimestamp":1716298140,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Abbott Laboratories is well-poised to grow in the coming quarters, backed by its Nutrition business, which continues to recover shares and grow its Adult business. Within Diabetes care, Libre’s solid sales trajectory is encouraging and should continue to sustain with several new growth opportunities. Strong potential in the Diagnostics space is highly promising as well.However, the company faces challenges from lower demand for COVID-19 testing, which is hurting growth, as well as adverse currency movements.In the past year, this Zacks Rank #3  stock has declined 4.4% compared with a 0.6% fall of the industry and a 26.6% rise of the S&P 500 composite.This renowned provider of a diversified line of healthcare products has a market capitalization of $181.08 billion. Abbott’s earnings surpassed estimates in three of the trailing four quarters and matched on one occasion, the average surprise being 2.4%.The company has been investing in science-based solutions to address the growing global","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1989763427.SGD":"CPR Invest - Food For Generations A2 Acc SGD-H","BK4568":"美国抗疫概念","SG9999002224.SGD":"Allianz Global High Payout SGD","BK4588":"碎股","MEDP":"Medpace Holdings Inc.","BK4082":"医疗保健设备","HIMS":"Hims & Hers Health Inc.","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","BK4535":"淡马锡持仓","LU1691799644.USD":"Amundi Funds Polen Capital Global Growth A2 (C) USD","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","BK4551":"寇图资本持仓","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4121":"生命科学工具和服务","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4581":"高盛持仓","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4504":"桥水持仓","ABT":"雅培","BK4548":"巴美列捷福持仓","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BNTX":"BioNTech SE","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4592":"伊斯兰概念","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","HITI":"High Tide Inc.","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4585":"ETF&股票定投概念","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4139":"生物科技","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","BK4007":"制药","BK4566":"资本集团","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","SG9999002232.USD":"Allianz Global High Payout USD","BK4196":"保健护理服务","LU2237957902.USD":"NIKKO AM GLOBAL EQUITY \"F\" (USD) ACC","LU1989763690.USD":"东方汇理世代食品基金A2 Acc","LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC"},"translate_title":"以下是你目前应该持有雅培股票的原因","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABT":1,"MEDP":1,"HITI":1,"HIMS":1,"BNTX":0.9},"content_text":"Abbott Laboratories (ABT) is well-poised to grow in the coming quarters, backed by its Nutrition business, which continues to recover shares and grow its Adult business. Within Diabetes care, Libre’s solid sales trajectory is encouraging and should continue to sustain with several new growth opportunities. Strong potential in the Diagnostics space is highly promising as well.\nHowever, the company faces challenges from lower demand for COVID-19 testing, which is hurting growth, as well as adverse currency movements.\nIn the past year, this Zacks Rank #3 (Hold) stock has declined 4.4% compared with a 0.6% fall of the industry and a 26.6% rise of the S&P 500 composite.\nThis renowned provider of a diversified line of healthcare products has a market capitalization of $181.08 billion. Abbott’s earnings surpassed estimates in three of the trailing four quarters and matched on one occasion, the average surprise being 2.4%.\nLet’s delve deeper.\nFactors at Play\nLibre Drives Diabetes Care: Abbott’s Diabetes Care business continued to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre. In a relatively short span, FreeStyle Libre has achieved global leadership among continuous glucose monitoring (CGM) systems for both Type 1 and Type 2 users. Last year, Libre became the first CGM system nationally reimbursed in France for basal insulin users in diabetes management.\nIn the first quarter of 2024, it obtained reimbursement from select institutional payers in Germany for basal insulin users also on oral medication, which, according to Abbott, hints at a broader coverage expansion across other European markets. As a major development, the company’s latest innovation, the FreeStyle Libre 2 Plus sensor, is available for the first time for Tandem Diabetes Care’s t:slim X2 insulin pump users in the United States.\nLibre has become the most successful medical device in history in terms of sales revenues, growing 23% year over year in the first quarter.   \nImage Source: Zacks Investment Research\nSales Recovery Within Nutrition: Following a setback related to the voluntary recall and production stoppage of certain infant powder formula products manufactured at its facility in Sturgis, MI, last year, Abbott’s U.S. infant formula business has strongly regained its market share since the beginning of 2023.\nIn the first quarter of 2024, the company reported robust growth in pediatric nutrition, driven by continued market share gains in the U.S. infant formula business and growth across the company’s international portfolio of infant formula and toddler nutrition brands. Adult nutrition is also gaining momentum, supported by the strong global sales performance of the nutrition brand Ensure.\nThe company has been investing in science-based solutions to address the growing global awareness of the benefits of nutrition products. In January, Abbott launched a new nutrition shake called PROTALITY, which provides nutritional support for adults pursuing weight loss.\nStrong Prospects Within Core Diagnostics: Growth in diagnostics continues to be led by the adoption of Abbott’s market-leading systems and demand for testing that takes place in a variety of settings, including hospitals, laboratories, urgent care centers, physician offices, retail pharmacies and blood screening facilities. On a global scale, ABT currently holds a prominent position in point-of-care testing, with a portfolio focused on four key areas — Infectious Disease, Cardiometabolic & Informatics, Toxicology and Consumer Diagnostics. In the first quarter of 2024, total diagnostics organic sales (excluding COVID testing) grew 5.4%.\nExcluding COVID-19 testing-related sales, global Core Laboratory Diagnostics sales increased 6.2% on an organic basis, led by the continued strong adoption of Abbott's Alinity family of diagnostics systems and testing portfolios. In April 2024, the company received FDA approval for i-STAT TBI, the company’s point-of-care diagnostic test that could help determine in 15 minutes if someone has suffered a mild traumatic brain injury or concussion.\nDownsides\nDeclining COVID-19 Testing Dents Growth: During the COVID-19 public health emergency, Abbott’s diagnostic tests witnessed stupendous revenue growth due to high demand for testing and government policies promoting healthcare access. However, following the pandemic’s official end in May 2023, the company has been experiencing a continuous decline in COVID-19 testing-related demand.\nIn the first quarter of 2024, Rapid Diagnostics sales fell 15.5% organically due to the lower demand for COVID-19 tests. In the upcoming months, too, this year-over-year decline in testing demand is expected to mar Abbott’s overall Diagnostics business sales growth.\nForeign Exchange Translation Impacts Sales: Foreign exchange is a major headwind for Abbott due to a considerable percentage of its revenues coming from outside the United States. The strengthening of the euro and some other developed market currencies continues to hinder the company’s international performance. In the first quarter of 2024, foreign exchange had an unfavorable year-over-year impact of 2.9% on sales.\nEstimate Trend\nIn the past 30 days, the Zacks Consensus Estimate for Abbott’s 2024 earnings has remained constant at $4.62.\nThe Zacks Consensus Estimate for the company’s 2024 revenues is pegged at $41.66 billion, which suggests a 3.9% rise from the year-ago quarter’s reported number.\nKey Picks\nSome better-ranked stocks in the broader medical space are High Tide HITI, Hims & Hers Health HIMS and Medpace MEDP.\nHigh Tide’s earnings are expected to surge 100% in 2024 compared with the industry’s 13.8%. HITI’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 91.7%. Its shares have surged 55% against the industry’s 0.6% fall in the past year.\nHITI sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nHims & Hers Health, sporting a Zacks Rank #1 at present, has an estimated 2024 earnings growth rate of a staggering 263.6% compared to the industry’s 18.2%. Shares of the company have increased 99.7% against the industry’s 25.9% fall over the past year.\nHIMS’ earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 79.2%. In the last reported quarter, it delivered an average earnings surprise of 150%.\nMedpace, also sporting a Zacks Rank #1 at present, has an estimated 2024 earnings growth rate of 27.1% compared to the industry’s 12.9%. Shares of MEDP have rallied 89.9% compared with the industry’s 5.1% rise over the past year.\nMEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.8%. In the last reported quarter, it delivered an average earnings surprise of 30.6%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nAbbott Laboratories (ABT) : Free Stock Analysis Report\nMedpace Holdings, Inc. (MEDP) : Free Stock Analysis Report\nHims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report\nHigh Tide Inc. (HITI) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.0","shortVersion":"4.24.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2437426174"}